Reliable markers for megakaryocytic reconstitution after peripheral blood stem cell transplantation (PBSCT) have not been established. To determine a convenient and reliable predictor, we measured the number of megakaryocyte progenitor cells in PBSC grafts by clonogenic and flow cytometric assays. Seventeen patients with hematological and solid malignancies were included in this study. For the clonogenic assay, we used thrombopoietin (TPO) as a growth factor to evaluate the maximum number of megakaryocyte progenitor cells. Using a flow cytometric assay, we examined the expression of platelet glycoproteins on CD34
and the time to granulocyte recovery. [7] [8] [9] As for platelet recovery, few studies have been reported; some have shown that the number of CFU-GM and CD34
+ cells correlate with platelet recovery, [7] [8] [9] [10] [11] [12] [13] [14] but others have not shown a significant correlation. 15, 16 Recently, specific markers for megakaryocyte progenitors such as colony-forming unit megakaryocyte (CFU-MK) and CD34 + /CD41 + or CD34 + /CD61 + cells have predicted platelet engraftment in PBSCT. 13, 14, 16, 17 Thrombopoietin (TPO), the ligand for the c-mpl receptor, has been shown to stimulate the growth of megakaryocyte colonies in vitro. [18] [19] [20] The number and size of CFU-MK induced by TPO was greater than that induced by any other combination of growth factors, suggesting that TPO may be useful for assaying CFU-MK. 21 Based on these observations, we analyzed the expression of different platelet glycoproteins on CD34
+ cells by flow cytometry and the number of TPO-induced CFU-MK in PBSC grafts. In addition, we examined the correlation between these parameters and platelet recovery to find a practical parameter to assess the capacity for platelet reconstitution after PBSCT.
Materials and methods

Patients
Seventeen patients with hematologic and solid malignancies were included; three with acute myelogenous leukemia (AML), three with acute lymphoblastic leukemia (ALL), seven with non-Hodgkin's lymphoma (NHL), two with Hodgkin's disease (HD), one with anaplastic large cell lymphoma (ALCL), and one patient with small cell lung cancer (SCLC). Patient characteristics and the details of PBSCT are shown in Table 1 . Ten patients received recombinant human granulocyte colony-stimulating factor (rhG-CSF; Kirin Brewery, Tokyo, Japan) after PBSCT at doses of 50 or 150 g/m 2 , but seven patients did not. Prior to the start of studies, informed consent was obtained from all patients.
Mobilization and procurement of PBSCs
Hematopoietic stem cells were mobilized into blood by high-dose chemotherapy consisting of cytosine arabinoside (Ara-C) (12 mg/m ) followed by 50 g/m 2 of rhG-CF. rhG-CSF was subcutaneously administered beginning on the second day after the last course of chemotherapy MNC, CD34, CFU-GM, CFU-MK: number of cells infused. Platelet recovery: days to reach Ͼ50 × 10 9 /l platelets. MNC = mononuclear cell; CD34 = CD34 + cells; CFU-MK = colony-forming unit megakaryocyte; F = female; M = male; HD = Hodgkin's disease; NHL = non-Hodgkin's lymphoma; AML = acute myelogenous leukemia; ALL = acute lymphoblastic leukemia; SCLC = small cell lung cancer; ALCL = anaplastic large cell lymphoma; Ara-C = cytarabine; CY = cyclophosphamide; ETP = etoposide; MCNU = ranimustine; BU = busulfan; CBDCA = carboplatin; TBI = total body irradiation; CR = complete remission; PR = partial response.
and continued until the completion of leukapheresis. 2, 5 Peripheral blood mononuclear cells were collected on 2-3 consecutive days during the recovery phase from myelosuppression using a CS3000 blood cell separator (Fenwal, Deerfield, IL, USA). Leukapheresis was usually started when the number of CD34 + cells in peripheral blood determined by flow cytometry reached 20/l. The leukapheresis product was stored with 5% dimethylsulfoxide (DMSO), 6% hydroxyethyl starch (HES), and 4% human albumin. For in vitro assays, 1.8 ml of the leukapheresis products were stored in a 2 ml polypropylene tube at Ϫ80°C. For clinical use, cells were transferred into 100 ml freezing bags and cryopreserved at Ϫ130°C.
In vitro assays
Samples were rapidly thawed in a 37°C waterbath until ice crystals disappeared. Samples were then diluted slowly with buffer containing 7.5 ml RPMI 1640 medium (RPMI), 0.5 ml ACD-A, and 50 U/ml DNase, for 15 min in an icebath, then washed once in RPMI. All samples were diluted 1:3 with RPMI, layered over Ficoll-Hypaque (Nacalai Tesque, Kyoto, Japan) and centrifuged at 450 g for 30 min. Light-density mononuclear cells were collected, washed twice in RPMI, and resuspended in Iscove's modified Dulbecco's medium (IMDM). The number of cells were counted and viability was assessed by trypan blue dye exclusion. Post-thawing recovery rates of PBSC were evaluated by dividing the total number of PBSC after thawing by the total number prefreezing.
CFU-GM assay
Cells (1 ϫ 10 5 ) were cultured in 1 ml of IMDM containing 10 ng of G-CSF, 10 ng of GM-CSF, 100 U IL-3, 2 U EPO (all gifts from Kirin Brewery), 20% FCS (Flow Laboratories, McLean, USA), 2 mm l-glutamine, and 1% methylcellulose. After 14 days, cell aggregates containing more than 40 cells were counted as colonies using an inverted microscope.
CFU-MK assay
Cells (1 ϫ 10 5 ) were cultured in 1% methylcellulose supplemented with IMDM, 25% human AB plasma, 5 ϫ 10 Ϫ5 mol/l 2-mercaptoethanol, 2 mm l-glutamine, 100 ng/ml rh stem cell factor (SCF), and 50 ng/ml thrombopoietin (TPO) (gifts from Kirin Brewery). Cells were incubated at 37°C in 100% humidified 5% CO 2 atmosphere. After 14 days, the number of CFU-MK colonies were counted in each well under an inverted microscope. Cell aggregates containing more than four cells were scored as colonies. Individual colonies were removed with micropipettes under the inverted microscope and transferred to slides by cytospin. Slides were stained with Wright-Giemsa for morphologic identification and for immunostaining using alkaline phosphatase/anti-alkaline phosphatase (APAAP, DAKO LSAB Kit, Carpinteria, CA, USA) to examine the expression of platelet glycoprotein IIb (CD41b, Nichirei, Tokyo, Japan). Slides were counterstained with hematoxylin (MUTO PURE Chemicals, Tokyo, Japan) for 5 min.
CD34-positive cell selection
Cells were thawed, separated with Ficoll-Hypaque, washed and resuspended in IMDM, then processed for CD34
+ cells with a MACS CD34 progenitor cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Samples were centrifuged at 400 g for 10 min and resuspended in 300 l of PBS containing 0.5% BSA and 5 mm EDTA. Cells were incubated with 100 l of reagent A1 (human IgG) for blocking and 100 l of reagent A2 (monoclonal anti-CD34, QBEND-10) for 15 min at 4°C. Cells were then resuspended in 400 l of buffer, followed by 100 l of reagent B (sheep anti-mouse IgG-coated immunomagnetic beads), incubated for 15 min on ice, then washed with buffer. Cells were sorted twice using the miniMACS Cell Separator, then resuspended for flow cytometric analysis.
Flow cytometric analysis
Before and after sorting CD34
+ cells, cells were washed twice with PBS containing 2% FCS (Flow Laboratories) and 0.1% sodium azide (PBS-azide), then incubated with 750 g of purified immunoglobulin G (IgG, Green Cross, Tokyo, Japan) for 30 min at 4°C to block Fc receptors prior to the addition of specific antibody. Cells were then incubated with monoclonal anti-CD34-PE (Becton Dickinson, San Jose, CA, USA) and further analyzed for the expression of megakaryocyte markers as follows: CD41a-FITC (Immunotech, Marseille, France), CD41b-FITC (Nichirei), CD42a-FITC (Becton Dickinson) and CD42b-FITC (DAKO, Denmark). As negative controls, IgG1-PE and IgG1-FITC (Becton Dickinson) were used. Cells were washed twice and resuspended in 0.5 ml of PBS-azide. Flow cytometric analysis was performed using an EPICS Profile flow cytometer (Coulter, Hialeah, FL, USA) as previously described. 22 
Statistical analysis
The Spearman rank correlation was used to evaluate all relationships between variables. A value of P Ͻ 0.05 was accepted as statistically significant.
Results
Hematopoietic recovery after PBSCT
Following pretransplant conditioning, a mean of 2.7 ϫ 10 (Table 1) . Hematopoietic recovery after PBSCT was rapid except in the three patients with acute leukemia. These three patients received PBSCT in first remission and were not heavily pre-treated but received relatively low numbers of CFU-MK (Table 1 ). The median number of days to reach neutrophils Ͼ0.5 ϫ 10 9 /l and platelets Ͼ50ϫ 10 9 /l were 11 (range 8-17 days) and 15 days (range 9-110 days), respectively.
Relationship between the numbers of MNC or CFU-GM infused and platelet recovery
All patients reconstituted hematopoietic function after PBSCT, even those with low numbers of MNC (0.7 ϫ 10 or CFU-GM infused and the time to platelet recovery (r = Ϫ0.26 and Ϫ0.40, respectively).
Relationship between the number of CFU-MK infused and platelet recovery
The number of cells in some CFU-MK were 20-50 in our assay system using TPO as a growth factor. CFU-MK had a thin and highly refractive cell membrane; the cytoplasm was translucent and nongranular ( Figure 1 ). WrightGiemsa-stained preparation showed that megakaryocytes had two or more irregular nuclei. Cells comprising CFU-MK colonies all had positive reactivity to antibody against CD41b. The number of CFU-MK in PBSC grafts varied widely (mean number of CFU-MK per 1 ϫ 10 5 MNC plated was 13.64, range 2.0-163.0). The number of CFU-MK infused did correlate with the time to platelet recovery (r = Ϫ0.55, P = 0.0348) ( Figure 2 , Table 2 ). 
Relationship between the number of CD34 + cells infused and platelet recovery
The percentage of CD34 + cells in the PBSC grafts had a mean of 3.1% (range 0.2-11.6%). The median number of CD34 + cells infused was 4.9 ϫ 10 6 /kg; no correlation was observed between the number of CD34
+ cells infused and platelet recovery (r = Ϫ0.27) (Figure 3) .
Expression of platelet glycoproteins on CD34 + cells and platelet recovery
The purity of the final product after CD34 + selection ranged from 69.5 to 100% with a mean of 95.3 Ϯ 1.5%. The relationships between the number of CD34 + cells infused expressing CD41a, CD41b, CD42a, and CD42b and the time to platelet recovery are shown in Table 2 . The number of CD34
+ /CD41a+ cells infused had the strongest inverse correlation with platelet recovery (r = Ϫ0.60, P = 0.0205) ( Figure 4 , Table 2 ).
In addition, a positive correlation was observed between the number of CD34 megakaryocyte progenitors (r = 0.84, P = 0.0018) ( Figure 5 ).
Discussion
It is critical to determine how many hematopoietic stem or progenitor cells are necessary for engraftment as well as how to appraise the PBSC collection product. Reports concerning the relationship between the number of MNC, CFU-GM, CD34
+ cells, and hematopoietic recovery after PBSCT are sometimes contradictory. Measurement of the number of MNC infused is the easiest method, but the wide variation in the percentage of progenitor cells within PBSC makes MNC an unreliable determinant. 7, 12 Our study showed that the number of MNC is not correlated with platelet recovery (r = Ϫ0.26). The number of CFU-GM was shown to be closely correlated with the time to neutrophil recovery; some studies have reported that the number of CFU-GM is correlated with platelet recovery after PBSCT. 10, 11, 14 One study has shown a correlation between the number of CFU-GM and both neutrophil and reticulocyte recovery, but not platelet recovery. 23 In the present study, the mean number of CFU-GM infused was 7.2 ϫ 10 5 /kg, more than the reported threshold value of 2 ϫ 10 5 /kg for neutrophil and platelet recovery. 24 However, the correlation between the number of CFU-GM infused and platelet recovery was poor, which was in contrast to the report by Takamatsu et al 14 who showed positive correlation of the number of CFU-GM with neutrophil, platelet and reticulocyte recovery. One reason for this might depend on the assay systems used in each laboratory.
As a predictor for platelet recovery, the number of CFU-MK in this study was better than CFU-GM. A significant correlation between the number of CFU-MK infused and platelet recovery has been reported. 14, 16 However, the CFU-MK assay has yielded variable results, in part, because best growth is obtained with a combination of growth stimulators, colony size can be quite small, and colony identification can present problems to the inexperienced observer. 25 In the present study, we used TPO and SCF as growth factors for CFU-MK; these produce more and larger colonies than previous methods, [18] [19] [20] [21] and these CFU-MK characteristics were inversely correlated with the time to platelet recovery (r = Ϫ0.55). Although colony assays are reliable with TPO, the method is laborious and requires 2 weeks to obtain results, making it generally unsuitable for use as a routine method in a clinical laboratory.
The measurement of CD34 + cells by flow cytometry has been widely used as a predictor for hematopoietic recovery after PBSCT. [7] [8] [9] 12, 13, 16 The optimal number of CD34 + cells for rapid and consistent engraftment in PBSCT is 5.0 ϫ 10 6 /kg. 12 In the present study, the correlation between the number of CD34 + cells and platelet recovery was not significant (r = Ϫ0.27), in contrast to previous reports. 13, 17 Various subsets of CD34 + cells may correlate with neutrophil and platelet recovery. Dercksen et al 17 reported that CD34 + /CD41 + cells had a significantly better correlation with time to platelet recovery than the total number of CD34 + cells. In the present study, we examined the expression of platelet menbrane glycoprotein IIb/IIIa (CD41a, CD41b) and Ib/Xa (CD42a, CD42b) on the CD34 + cells in PBSC graft. Expression of almost all these glycoproteins on CD34
+ cells was within 5%. A number of studies have reported the presence of platelet glycoproteins on CD34 + cells; [26] [27] [28] between 2 and 90% of CD34 + cells reacted with antibodies to CD41 and CD61. This variation may be due to adherence of platelets to CD34 + cells. We therefore used buffer containing EDTA to block platelet adhesion as reported by Dercksen et al. 17 Correlative coefficients for CD41a, CD41b, CD42a, and CD42b with platelet recovery were Ϫ0.60, Ϫ0.35, Ϫ0.42, and Ϫ0.09, respectively. As compared with other markers, the number of CD34 + /CD41a + cells had the strongest relationship and the number of CD34 + /CD42b + cells were not correlative with the time to platelet recovery. One reason for this variation in the relationship between glycoprotein expression and platelet recovery could be differences in the stage of megakaryocytic differentiation detected by each glycoprotein. Glycoproteins IIb and IIIa (CD41a, CD41b) are reported to be expressed first during megakaryocytic differentiation, while glycoprotein Ib (CD42a, CD42b) appears to be a later marker. 26, [29] [30] [31] In conclusion, this is the first report to examine the correlation between the numbers of CFU-MK and CD34 + /CD41a + cells infused and the time to platelet recovery, as well as the correlation between the number of CFU-MK and CD34 + /CD41a + cells. The threshold for rapid platelet recovery was 1 ϫ 10 5 /kg CD34 + /CD41a + cells or 1 ϫ 10 5 /kg CFU-MK. Our data suggest that the number of CD34 + /CD41a + cells is a convenient and reliable marker for platelet recovery after PBSCT.
